4D Molecular is a late-stage gene-therapy company concentrating its main value on 4D-150, which it is developing as a longer-acting treatment for wet AMD and diabetic macular edema. Its wet-AMD Phase 3 program is already running, and management had previously targeted a DME Phase 3 start in the third quarter of 2026; the company also says its current plan is funded into the second half of 2028.
The main change is execution, not a new strategic pivot. The company has now enrolled the first patients in 4SIGHT, a global, randomized, double-masked Phase 3 trial comparing 4D-150 with aflibercept in 514 treatment-naïve DME patients. The primary test is whether vision outcomes are no worse than aflibercept at Week 52, with injection reduction as a key secondary outcome. This confirms delivery against the previously stated Q3 launch timeline, so the start itself is partly anticipated rather than a major surprise.
The trial is designed to test the commercial proposition that matters: similar vision with fewer injections. Both treatment arms receive five aflibercept loading doses, and randomization requires evidence that patients respond to aflibercept during the run-in period. That should make the comparison more clinically relevant, but it also means the study is selecting for treatment-responsive patients rather than representing every DME patient. 〔0〕
| Filing metric | Reported result | Comparison / context |
|---|---|---|
| 4SIGHT enrollment target | 514 patients | Phase 3 DME trial |
| SPECTRA safety population | 22 patients | Two-year follow-up |
| SPECTRA Phase 3-dose efficacy cohort | 9 patients | 3E10 vg/eye |
| Mean BCVA change | +10.8 letters | Phase 3-dose cohort |
| Mean CST change | -176 µm | Phase 3-dose cohort |
| Supplemental injections per patient | 5.2 | 61% below projected 13.0 with aflibercept Q8W |
| Estimated supplemental injections per patient | 3.2 | 75% retrospective reduction using 4SIGHT criteria |
| Injection-free patients | 2 of 9, or 22% | Phase 3-dose cohort |
The two-year SPECTRA update is supportive, but not decisive clinical proof. The company reports no intraocular inflammation at any timepoint and no ocular serious adverse events in the 22-patient safety population. The efficacy signal is encouraging, particularly the reported injection reduction, but the most relevant numbers come from only nine patients and the 75% figure is explicitly a retrospective estimate based on different supplemental-injection criteria; actual 4SIGHT results may differ.
Regulatory alignment modestly lowers development uncertainty, but does not remove trial risk. 4DMT says U.S. and European regulators are aligned on the possibility of filing from a single DME Phase 3 study using combined 4D-150 data, including the SPECTRA and PRISM studies and the wet-AMD Phase 3 program. That could make a successful 4SIGHT result more valuable, but the filing provides no new efficacy readout from the pivotal study and no guarantee that regulators will ultimately accept the package.
Bottom line: This advances 4D-150 from planned DME development into active pivotal testing and adds encouraging long-term, lower-burden data. The business impact is meaningful, but the supporting SPECTRA efficacy cohort is too small to settle whether the pivotal program will work; that remains the key unanswered question.
Read the original 8-K on SEC EDGAR ↗